Press Releases
FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol* for Maintenance Treatment of COPD
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) recommended that clinical data included in a...
Press Releases
Regional Cancer Care Associates Expands Footprint in New Jersey
Regional Cancer Care Associates (RCCA), New Jersey’s largest oncology physician network and one of the largest in the nation, is pleased to announce that...
Press Releases
Direct Flow Medical Receives CE Mark for Transcatheter Aortic Heart Valve System That Virtually Eliminates Aortic Regurgitation
Direct Flow Medical, Inc., a transcatheter heart valve innovator focused on improving patient outcomes, announced that it has received CE Mark (Conformité Européenne) for...
Press Releases
Domain Therapeutics grants Prexton Therapeutics an exclusive option to license and develop mGluR4 PAMs for Parkinson s Disease
Domain Therapeutics S.A. announced today that Domain Therapeutics grants Prexton Therapeutics (Geneva, Switzerland) an exclusive option to license and develop metabotropic glutamate receptor 4 (mGluR4)...
Press Releases
Almac Successfully Completes Knowledge Transfer Partnership with Queens University with Highest Accolade
Almac is pleased to announce the successful completion of the Knowledge Transfer Partnership (KTP) with Queens University Belfast, to develop, improve and embed bioprocesses...
Press Releases
BASi Launches Culex NxT Next Generation In Vivo Automated Sampling System
BASi (Bioanalytical Systems, Inc.) today announced the launch of Culex® NxT, the latest generation of the Company’s proprietary in vivo automated sampling system. The...
Press Releases
Celator® Pharmaceuticals Enrolls First Patient in Its Phase 3 Study of CPX-351 in Untreated High-Risk Acute Myeloid Leukemia
Celator Pharmaceuticals today announced that the first patient has been treated in its Phase 3, multicenter, randomized, open-label clinical trial of CPX-351 (cytarabine:daunorubicin) Liposome...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.